로딩 중…
지수 로딩 중…
EyeGene Inc.
185490· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,383-1.64%
2026-06-19
Price Chart
EyeGene Inc.-50.38%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 59.79B KRW |
| Revenue | 4.02B KRW |
| Net Income | -9.45B KRW |
| Total Assets | 64.70B KRW |
| Net Assets | 50.92B KRW |
| Employees | 50 |
| Value | |
| P/B | 1.17x |
| P/S | 14.87x |
| FCF Yield | -10.18% |
| Profitability | |
| ROE | -18.56% |
| ROA | -14.61% |
| Op. Margin | -244.98% |
| Revenue Growth | 55.55% |
| Financial Health | |
| Debt Ratio | 27.06% |
| Total Debt | 0 KRW |
| FCF | -6.08B KRW |
| Cash | 7.16B KRW |
| Current Ratio | 4.37x |
| Performance | |
| 1Y Return | -50.38% |
| 1M Return | -38.12% |
| From 52W High | -60.10% |
| 1Y MDD | -64.99% |
| Trading | |
| Volume | 222,062 shares |
| Foreign Own. | 2.56% |
| Per Share | |
| EPS | -468 KRW |
| BPS | 1,247 KRW |
Company Info
Eyegene, a bio venture founded in 2000 for proteomics and immunology research, established mRNA subsidiary Renaim and operates EyeGene Australia in 2021. The company's core focus is developing mRNA vaccines and AAV gene therapies, with gene and cell therapies at its center, having completed Phase 1/2a clinical trials for a COVID-19 preventive vaccine. It collaborates with five domestic and international companies on next-generation mRNA vaccine development and prioritizes technology acquisition through revenue-generating business and venture enterprise investments. Eyegene is headquartered in Uiwang-si, Gyeonggi-do.